In a nutshell This study aimed to investigate pembrolizumab (Keytruda) before and after surgery in patients with early triple-negative breast cancer (TNBC). This study concluded that the addition of pembrolizumab to chemotherapy before surgery and after surgery for TNBC improved the survival without complications from TNBC in these...
Read MoreCurrent stage-Stage II Posts on Medivizor
Aromatase inhibitors versus tamoxifen for premenopausal women with hormone positive early-stage breast cancer treated with ovarian suppression.
In a nutshell This study compared the effectiveness of aromatase inhibitors (AIs) versus tamoxifen (Nolvadex) for the treatment of premenopausal patients with estrogen receptor-positive (ER+) early-stage breast cancer (BC) treated with ovarian suppression. The data showed that AIs significantly reduced the risk of BC recurrence compared...
Read MoreEvaluating the long-term effectiveness and safety of adding carboplatin with or without veliparib to standard chemotherapy given before surgery in patients with triple‑negative breast cancer.
In a nutshell This study reported the long-term effectiveness and safety of adding carboplatin (Paraplatin) with or without veliparib (ABT-888) to standard chemotherapy given before surgery (neoadjuvant chemotherapy; NACT) in patients with early-stage triple-negative breast cancer (TNBC). The data showed that the addition of carboplatin to standard NACT...
Read MoreComparing effectiveness of intraoperative radiotherapy and whole breast irradiation in patients with early breast cancer
In a nutshell This study aimed to investigate the oncological effectiveness of intraoperative radiotherapy (IORT) and whole breast irradiation (WBI) for patients with early breast cancer (BC). This study concluded that there was a high oncological effectiveness for both groups of patients. Some background Intraoperative...
Read MoreExtended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.
In a nutshell This study compared the effectiveness and safety of extended therapy with letrozole (LET; Femara) for 5 years versus the standard therapy of 2-3 years for the treatment of postmenopausal women with early-stage breast cancer (BC). The data showed that extended treatment with LET for 5 years significantly improved the survival outcomes...
Read MoreEvaluating short-course radiation therapy followed by chemotherapy for patients with rectal cancer.
In a nutshell This study evaluated short-course radiation therapy (RT) followed by chemotherapy as a non-surgical treatment of patients with rectal cancer (RC). The data showed that treatment with short-course RT and chemotherapy is safe and effective for these patients. Some background Colorectal cancer (CRC) is one of the most common types of...
Read MoreDoes tyrosine kinase inhibitors therapy after surgery benefit patients with EGFR-mutant resected NSCLC?
In a nutshell This study evaluated whether patients with non-small-cell lung cancer (NSCLC) having genetic mutations could benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) therapy after surgery. The data showed that EGFR-TKI therapy after surgery significantly improved survival without disease progression in...
Read MoreDoes lumpectomy followed by radiation improve survival outcomes in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes?
In a nutshell This study evaluated the survival outcomes after lumpectomy followed by radiation versus mastectomy alone in patients with early-stage HER2-positive (HER2+) breast cancer (BC) and triple-negative breast cancer (TNBC) with low or high tumor-infiltrating lymphocytes (TILs). The data showed that lumpectomy followed by radiation improves...
Read MoreIs a regimen of weekly chemotherapy with trastuzumab and pertuzumab as effective as standard treatment options for HER2-positive breast cancer
In a nutshell This study examined the use of paclitaxel (Taxol) and carboplatin (Paraplatin) as weekly chemotherapy (CT) with trastuzumab (Herceptin) and pertuzumab (Perjeta) in HER2+ breast cancer (BC) in order to reduce toxicity rates. The authors found that the weekly regimen of chemotherapy can be considered an alternative to standard chemotherapy...
Read MoreEvaluating outcomes of laparoscopic surgery for the treatment of elderly patients over 80 years with colorectal cancer.
In a nutshell This study evaluated the short- and long-term outcomes of laparoscopic surgery (LS; keyhole surgery) for the treatment of elderly patients with colorectal cancer (CRC) aged over 80 years. The data showed that LS is a good and safe option for these patients. Some background Colorectal cancer (CRC) is one of the most common types of cancer...
Read MoreEvaluating the effectiveness and safety of total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
In a nutshell This study investigated the effectiveness and safety of total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy (CRT) for the treatment of patients with locally advanced rectal cancer (LARC). The data showed that TNT was associated with improved outcomes compared with standard CRT for these patients. Some background...
Read MoreWhat is the best timing for chemotherapy after surgery in patients with early-stage breast cancer?
In a nutshell This study looked at the timing of chemotherapy (CT) after surgery in the treatment of early breast cancer (BC). The authors found that CT given within 31 days after surgery may improve survival in patients with triple-negative (TN) BC. Some background BC is one of the most common types of cancer found in women. There are...
Read More